Compare prices and buy CJC-1295 + Ipamorelin Blend from 42 research peptide vendors - also called suppliers or sources. Updated daily.
A two-peptide blend pairing ipamorelin, a ghrelin-receptor agonist, with CJC-1295, normally the No DAC form, a GHRH analog for which FDA identified no studies establishing pharmacological activity. The pairing is a market convention rather than a demonstrated pharmacological one, and no controlled human trial has evaluated the combination. Neither component is FDA-approved.
For research purposes only. Not medical advice.
The CJC-1295 + Ipamorelin blend is a fixed combination of two research peptides in one vial: CJC-1295 No DAC, an analog of growth hormone-releasing hormone, and ipamorelin, a ghrelin-receptor agonist. It is a mixture rather than a distinct chemical entity, so it carries no CAS number of its own, and no pharmacopeia recognizes it as a substance. The name is descriptive, unlike trade names such as GLOW or Wolverine.
Two molecules are sold under the CJC-1295 name, and this blend almost always pairs ipamorelin with the no-DAC form, molecular formula C152H252N44O42. CJC-1295 With DAC, C165H269N47O46, carries an appended group that bonds covalently to serum albumin after injection.
Most vendors mark the distinction in the title, the URL or a size attribute, and where it is marked it is the no-DAC form. A bare "CJC-1295 + Ipamorelin" is ambiguous on its face, and the molecular formula on the certificate of analysis is the only reliable check. It is a price question as much as an identity one, since vendors price the DAC form at a higher tier.
Ipamorelin agonizes the ghrelin receptor, GHS-R1a, on pituitary somatotrophs, prompting the gland to release its own growth hormone in pulses. The 1998 study behind its description as a selective secretagogue is on the ipamorelin page.
CJC-1295 No DAC belongs to the GHRH-receptor family alongside sermorelin and tesamorelin, but the evidence behind it is thinner than the pairing implies. Reviewing the substance in 2024, the FDA reported that it identified no studies establishing whether CJC-1295 free base or its acetate are pharmacologically active. The published growth hormone results belong to the DAC form.
The rationale for pairing them is that the two receptors are distinct and their effects were shown to combine. Bowers and colleagues reported in the Journal of Clinical Endocrinology and Metabolism in 1990 that GHRP-6 given with native GHRH released more growth hormone in healthy men than either did alone. Neither molecule in that study is in this vial, no controlled trial has evaluated this combination, and the pairing is a market convention rather than a pharmacological one.
PeptideScouter records a blend's size as the total peptide content of the vial, so at 1:1 the like-for-like benchmark is a simple average of the two component prices.
Nothing dominates the mass here, which makes the figure easier to read than GLOW, where one ingredient is most of the vial and pulls the per-milligram price toward itself.
Neither component is an FDA-approved drug, and the blend as sold is not a compounded prescription product. The two substances travelled the same path and ended in different places.
As of October 2026, ipamorelin acetate remains in Category 2 under the separate 503B interim policy, while CJC-1295 appears only in the "nominated but withdrawn" table of FDA's Category 2 page, which keeps the safety text with the entry. Category 2 membership is decided per substance and per compounding pathway, so one component's status says nothing about the other's.
Research-grade material sold by the vendors indexed here is offered for laboratory research use only and not for human consumption.
The blend combines CJC-1295 and ipamorelin in a single vial, nearly always 1:1: a 10 mg vial holds 5 mg of each peptide and a 20 mg vial holds 10 mg of each. An unequal split is rare. The CJC-1295 component is almost always the no-DAC form rather than the albumin-binding DAC version. Material sold by research peptide vendors is offered for laboratory use only, not for human consumption.
Two different molecules are sold under the CJC-1295 name: the no-DAC form, molecular formula C152H252N44O42, and CJC-1295 With DAC, C165H269N47O46, which carries an appended group that binds covalently to serum albumin. Blend listings that mark the difference at all mark it as no DAC, but a title reading only CJC-1295 plus ipamorelin does not say, and the molecular formula on the certificate of analysis is the only reliable check. It is a price question too, since vendors price the DAC form at a higher tier than the no-DAC form.
A CAS Registry Number identifies a single chemical substance, and this blend is a mixture of two. The registry number for the no-DAC form is itself unsettled, since vendors print one number while the FDA's 2024 review of the substance uses another, so PeptideScouter verifies that component against its molecular formula, C152H252N44O42, rather than against a number. A certificate of analysis for a blend should report each component separately.
Comparing them takes care, because PeptideScouter records the blend's size as the total peptide content of the vial. A 10 mg blend vial holds 5 mg of each component, so its price per milligram is not comparable to that of a 10 mg single-peptide vial. At a 1:1 split the like-for-like benchmark is the average of the two component prices. The price table on this page lists the blend's own listings, and each component's live prices are on its own page.
No. Nominations to the Section 503A bulk drug substances list are made per substance, and no combination product was before the Pharmacy Compounding Advisory Committee. Both components were reviewed on their own in late 2024, after their nominations were withdrawn, and the committee voted against every ipamorelin and CJC-1295 substance it heard. Those votes are advisory, the FDA changes the list only through notice-and-comment rulemaking, and none of it applies to research-grade material sold by peptide vendors.
CJC-1295 + Ipamorelin Blend is sold by 42 research peptide vendors indexed on PeptideScouter, with 72 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
40 of the 42 indexed vendors currently have CJC-1295 + Ipamorelin Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Renova Peptides currently lists CJC-1295 + Ipamorelin Blend at $2.00/mg, the lowest listed price across 42 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.80/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 42 vendors listing CJC-1295 + Ipamorelin Blend publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.00/mg listed to $1.80/mg at Renova Peptides. Each vendor's code is shown beside its price in the table above.
CJC-1295 + Ipamorelin Blend ranges from $2.00/mg to $10.90/mg across 72 listings from 42 research peptide vendors, normalized to USD per milligram and refreshed daily.
42 research peptide vendors currently list CJC-1295 + Ipamorelin Blend on PeptideScouter, with 40 in stock right now. We track 72 listings across size and kit variants.
